Alzheimer's Disease Education and Referral Center

Composite MR Neuroimaging Marker for Alzheimer's Disease

Composite MR Neuroimaging Marker for Alzheimer's Disease

Overall Status: 
Enrolling by invitation
Brief Description: 

The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and people with Alzheimer's disease. The ultimate goal is to develop an early diagnostic tool for Alzheimer's. The study hypotheses are:

  • The fMRI index will differentiate between Alzheimer's disease, non-Alzheimer's dementia, and healthy volunteers.
  • The fMRI index will distinguish participants with MCI who convert to Alzheimer's disease from those who convert to a non-Alzheimer's dementia and those who remain stable.
  • MCI participants with a lower fMRI index at baseline who convert will progress to Alzheimer's sooner than those with a higher fMRI index, and MCI participants with a faster rate of fMRI index decline who convert will have an earlier onset of Alzheimer's disease.
Patient Qualifications: 
Min AgeMax AgeGenderHealthy Volunteers
50 Years
90 Years
Both
Yes
Inclusion Criteria: 

  • 60 years of age or older (50 years of age or older for frontotemporal dementia patients)
  • Normal memory, mild cognitive impairment (memory loss that does not significantly affect normal daily activities), or clinical diagnosis of Alzheimer's disease or frontotemporal dementia (includes primary progressive aphasia)
  • Right-handed
  • General good physical health

Exclusion Criteria: 

  • History of stroke or neurological disease (other than Alzheimer's disease or frontotemporal dementia)
  • Seizures or head injury with loss of consciousness within the last 5 years
  • Ferrous (magnetic) or electronic implants (due to the magnet in the MRI scanner)
  • Claustrophobia

Detailed Description: 

The onset of Alzheimer's disease is insidious, and the boundary between normal aging and Alzheimer's is blurred. To prevent and treat Alzheimer's, the investigators must be able to mark its preclinical stage, before brain damage becomes irreversible. There is a substantial body of research dealing with predictive markers of the disease in individuals with mild cognitive impairment (MCI). Despite these advances, researchers do not have enough evidence to recommend specific techniques that mark preclinical Alzheimer's disease.

A new functional MRI (fMRI) index may fill this gap. Participants will have two visits, one for memory testing and neurological examination and one for an MRI scan. Each visit will take approximately 1½ hours. For volunteers who wish to do so, all study procedures may be completed in a single visit. Participants with MCI will be followed annually.

The investigators are currently enrolling healthy volunteers as well as individuals with MCI (memory loss that does not significantly affect normal daily activities), Alzheimer's disease, and frontotemporal dementia (including primary progressive aphasia).

Locations: 
Map Marker CityStateZip CodeStatusPrimary Contact

Geolocation is 43.0513426, -88.0411993

Milwaukee
Wisconsin
53226
Name:
Phone:
Lead Sponsor: 
Agency
Medical College of Wisconsin
Collaborator Sponsor: 
Agency
National Institute on Aging (NIA)
Facility Investigators: 
NameRoleAffiliation
Shi-Jiang Li, PhD
Principal Investigator
Medical College of Wisconsin
Study Contact: 
NamePhoneEmail
Jennifer Jones
414-805-5232
Locations
 
 
ClinicalTrials.gov ID 
NCT01615666 (follow link to view full record on ct.gov in new window)
Official Title: 
A Composite MR Neuroimaging Marker for Alzheimer's Disease
Study Start Date: 
March 2009
Study End Date: 
March 2014
Disease Stage: 
Early
Middle
Enrollment: 
380